Celltrion Sees Little Threat From ‘Overheated’ Biosimilar Competition

Presenting Q2 Results, Korean Giant Questions Ability Of Smaller Players To Survive

 
• By Dave Wallace

Celltrion shrugged off challenges from smaller biosimilars players, calling out “overheated competition from new entrants” as it delivered its results and strategic developments for the second quarter of 2024, including pipeline updates paving the way for trials for its proposed Keytruda and Cosentyx biosimilars.

Small crowd of wooden figures next to large red wooden figure
Celltrion believes smaller biosimilars players will struggle to compete with larger outfits • Source: Shutterstock

Celltrion issued a stinging rebuke to smaller biosimilar competitors as the Korean biologics giant delivered its second-quarter results, declaring that “despite overheated competition from new entrants, only a few key players with strong portfolio and commercialization capabilities lead the market” in biosimilars.

In a section of its Q2 results presentation covering “changes in the competitive landscape of the biosimilar market,” Celltrion set out that it had identified 65 pharmaceutical companies that were developing biosimilar pipelines and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products